Published: 26 May 2026
Author(s): Blaž Burja, Marouane Boubaya, Cosimo Bruni, Lisa Christ, Lidia P. Ananyeva, Fabiola Atzeni, Christina Bergmann, Patricia E. Carreira, Jeska De Vries-Bouwstra, Nicoletta Del Papa, Antonella Marcoccia, Okada Masado, Gabriela Riemekasten, Edoardo Rosato, Tim Schmeiser, Marco Sprecher, Anna-Maria Hoffmann-Vold, Florian Kollert, Sabina Guler, Oliver Distler, Muriel Elhai, EUSTAR collaborators
Section: Original Article
In the large EUSTAR cohort, anti-Ro/SSA antibodies are detected in 15% of SSc patients and represent an independent risk factor for the presence and severity of ILD, particularly for cases with anti-Ro/SSA+/RF+ double positivity. These data support the inclusion of anti-Ro/SSA and RF antibodies in routine clinical practice to improve the risk stratification of SSc patients.
